Compare HOFT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOFT | AARD |
|---|---|---|
| Founded | 1924 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.4M | 165.8M |
| IPO Year | 1999 | 2025 |
| Metric | HOFT | AARD |
|---|---|---|
| Price | $13.11 | $5.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 29.9K | ★ 106.7K |
| Earning Date | 04-16-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $278,139,000.00 | N/A |
| Revenue This Year | $17.37 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | $128.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.62 | $3.35 |
| 52 Week High | $18.09 | $17.94 |
| Indicator | HOFT | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 44.11 |
| Support Level | $11.99 | $5.12 |
| Resistance Level | $13.63 | $6.43 |
| Average True Range (ATR) | 0.53 | 0.81 |
| MACD | -0.16 | -0.14 |
| Stochastic Oscillator | 14.95 | 22.17 |
Hooker Furnishings Corp is a designer, marketer, and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality, and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segments: Hooker Branded segment, Domestic Upholstery segment, and All Other. It generates the majority of its revenue from the Hooker Branded segment.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.